Board Member
Vanda Pharmaceuticals Inc. (VNDA)Equibles does not estimate personal net worth.
Get an email with a short summary when Vanda Pharmaceuticals Inc. publishes a filing, an earnings call transcript or a press release.
Get VNDA alertsMihael Polymeropoulos is recorded as Board Member at Vanda Pharmaceuticals Inc. (VNDA) since January 1, 2003 and CEO at Vanda Pharmaceuticals Inc. (VNDA). The newest filing on record that lists Mihael Polymeropoulos as CEO and Board Member at Vanda Pharmaceuticals Inc. (VNDA) is dated April 23, 2026. The proxy statement of Vanda Pharmaceuticals Inc. reports total compensation of $3,851,468 for Mihael Polymeropoulos in fiscal 2025, including a base salary of $965,655. Disclosed compensation is on record for 9 fiscal years. Mihael Polymeropoulos has spoken on 27 earnings calls across 1 company, most recently for Vanda Pharmaceuticals Inc. on October 28, 2026. Vanda Pharmaceuticals Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Vanda Pharmaceuticals Inc. includes Kevin Moran (CFO), Anne Sempowski Ward (Board Member), Charles C. Duncan (Board Member) and 5 others.
“Thank you for joining us today for Vanda Pharmaceuticals' third quarter, 2026 earnings conference call.”
“Thank you for joining us today for Vanda Pharmaceuticals' second quarter 2026 Earnings Conference Call. We are pleased with the continuous strong growth of FANAPT and the enthusiastic response to Nereus as it becomes available to patients.”
“Thank you for joining us today for Vanda Pharmaceuticals' first quarter 2026 earnings conference call.”
“Good afternoon, everyone, and thank you for joining Vanda Pharmaceuticals' fourth quarter and full year 2025 financial results conference call. 2025 was a year of strong commercial execution and significant regulatory and clinical advancements for Vanda.”
“This quarter reflects strong commercial execution with total net product sales reaching $56.3 million, up 18% year-over-year, led by a 31% increase in Fanapt sales and 35% growth in prescriptions.”
2003-01-01–present
Last confirmed April 23, 2026
Start not stated–present
Last confirmed April 23, 2026
Biotechnology · Healthcare
CEO, Board Member
2003-01-01–present
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Vanda Pharmaceuticals Inc. (VNDA) | President, Chief Executive Officer and Chairman of the Board | $965,655 | $3,851,468 |
| 2024 | Vanda Pharmaceuticals Inc. (VNDA) | President, Chief Executive Officer and Chairman of the Board | $933,000 | $3,896,241 |
| 2023 | Vanda Pharmaceuticals Inc. (VNDA) | President, Chief Executive Officer and Chairman of the Board | $897,000 | $3,720,215 |
| 2022 | Vanda Pharmaceuticals Inc. (VNDA) | President, Chief Executive Officer and Chairman of the Board | $815,140 | $4,269,410 |
| 2021 | Vanda Pharmaceuticals Inc. (VNDA) | President and Chief Executive Officer | $769,000 | $6,194,157 |
| 2020 | Vanda Pharmaceuticals Inc. (VNDA) | President and Chief Executive Officer | $746,235 | $2,913,420 |
| 2019 | Vanda Pharmaceuticals Inc. (VNDA) | President and Chief Executive Officer | $721,000 | $4,278,137 |
| 2018 | Vanda Pharmaceuticals Inc. (VNDA) | President and Chief Executive Officer | $700,000 | $4,024,728 |
| 2017 | Vanda Pharmaceuticals Inc. (VNDA) | President and Chief Executive Officer | $675,000 | $6,265,989 |
